Dr Reddy’s Laboratories (DRL) has received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection.
- The injection is a drug device product proposed for the treatment of acute migraine, in the American market.
- This is presented as a prefilled, ready to use, single dose disposable injector and are specifically designed for patients who experience firm migraine incident and for whom a pill may be the right option
Keys
- CEO and Co-Chairman of DRL -GV Prasad
- Executive Vice President Propriety Products Group of DRL– Raghav Chari
No comments:
Post a Comment